SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/09/12 Opko Health, Inc. 10-Q 9/30/12 60:6.7M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 456K 2: EX-2.8 Plan of Acquisition, Reorganization, Arrangement, HTML 287K Liquidation or Succession 3: EX-31.1 Certification -- §302 - SOA'02 HTML 25K 4: EX-31.2 Certification -- §302 - SOA'02 HTML 25K 5: EX-32.1 Certification -- §906 - SOA'02 HTML 19K 6: EX-32.2 Certification -- §906 - SOA'02 HTML 18K 40: R1 Document and Entity Information HTML 38K 30: R2 Condensed Consolidated Balance Sheets HTML 134K 38: R3 Condensed Consolidated Balance Sheets HTML 60K (Parenthetical) (Unaudited) 42: R4 Condensed Consolidated Statements of Operations HTML 116K (Unaudited) 55: R5 Condensed Consolidated Statements of Comprehensive HTML 39K Loss (Unaudited) 32: R6 Condensed Consolidated Statements of Cash Flows HTML 168K (Unaudited) 37: R7 Business and Organization HTML 29K 27: R8 Summary of Significant Accounting Policies HTML 41K 18: R9 Loss Per Share HTML 24K 56: R10 Composition of Certain Financial Statement HTML 55K Captions 44: R11 Acquisitions, Investments, and Licenses HTML 98K 43: R12 Discontinued Operations HTML 44K 48: R13 Fair Value Measurements HTML 86K 49: R14 Derivative Contracts HTML 43K 47: R15 Related Party Transactions HTML 40K 50: R16 Commitments and Contingencies HTML 26K 39: R17 Segments HTML 61K 41: R18 Subsequent Events HTML 23K 46: R19 Summary of Significant Accounting Policies HTML 100K (Policies) 60: R20 Composition of Certain Financial Statement HTML 54K Captions (Tables) 52: R21 Acquisitions, Investments, and Licenses (Tables) HTML 75K 34: R22 Discontinued Operations (Tables) HTML 39K 45: R23 Fair Value Measurements (Tables) HTML 85K 36: R24 Derivative Contracts (Tables) HTML 32K 15: R25 Segments (Tables) HTML 52K 53: R26 Summary of Significant Accounting Policies HTML 40K (Details) 57: R27 Loss Per Share (Details) HTML 28K 23: R28 Composition of Certain Financial Statement HTML 115K Captions (Details) 22: R29 Acquisitions, Investments, and Licenses (Details) HTML 70K 25: R30 Acquisitions, Investments, and Licenses (Details HTML 49K 1) 26: R31 Acquisitions, Investments, and Licenses (Details HTML 64K 2) 28: R32 Acquisitions, Investments, and Licenses (Details HTML 286K Textual) 14: R33 Discontinued Operations (Details) HTML 34K 51: R34 Discontinued Operations (Details 1) HTML 34K 33: R35 Discontinued Operations (Details Textual) HTML 23K 35: R36 Fair Value Measurements (Details) HTML 41K 17: R37 Fair Value Measurements (Details 1) HTML 73K 59: R38 Fair Value Measurements (Details 2) HTML 41K 13: R39 Fair Value Measurements (Details Textual) HTML 38K 29: R40 Derivative Contracts (Details) HTML 33K 54: R41 Related Party Transactions (Details) HTML 239K 16: R42 Commitments and Contingencies (Details) HTML 33K 21: R43 Segments (Details) HTML 42K 24: R44 Segments (Details Textual) HTML 30K 31: R45 Subsequent Events (Details) HTML 34K 58: XML IDEA XML File -- Filing Summary XML 88K 20: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 1.03M 7: EX-101.INS XBRL Instance -- opk-20120930 XML 1.31M 9: EX-101.CAL XBRL Calculations -- opk-20120930_cal XML 186K 10: EX-101.DEF XBRL Definitions -- opk-20120930_def XML 592K 11: EX-101.LAB XBRL Labels -- opk-20120930_lab XML 1.25M 12: EX-101.PRE XBRL Presentations -- opk-20120930_pre XML 848K 8: EX-101.SCH XBRL Schema -- opk-20120930 XSD 187K 19: ZIP XBRL Zipped Folder -- 0001193125-12-463415-xbrl Zip 146K
EX-31.1 |
Exhibit 31.1
CERTIFICATION
I, Phillip Frost, certify that:
(1) | I have reviewed this Quarterly Report on Form 10-Q of OPKO Health, Inc.; |
(2) | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
(3) | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
(4) | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
(5) | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: November 9, 2012 | ||||||
Phillip Frost, M.D. | ||||||
Chief Executive Officer |
40
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 11/9/12 | 4 | ||
For Period end: | 9/30/12 | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/18/21 Opko Health, Inc. 10-K 12/31/20 111:16M |